SB 241 (see companion bill HB 2529) – Texas

Status: Enacted
Year Introduced: 2023
Link: https://capitol.texas.gov/BillLookup/History.aspx?LegSess=88R&Bill=SB241

Relating to written notification provided by drug manufacturers regarding the cause of generic or biosimilar insulin prescription drug unavailability.


Return to Database Search

© 2018- The SLIHCQ DatabaseInitial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.

Associated Litigation:

No items found